麻豆传媒

Dr. Bruno is a medical oncologist and clinical researcher with a focus on lung cancer and other thoracic malignancies such as thymomas/thymic carcinomas as well as mesothelioma. As such, she conducts clinical trials investigating the safety and efficacy of new and promising therapies for those diseases, and is the institutional Principal Investigator of many NCI- and industry-sponsored studies at all phases of clinical drug development.
Participation in clinical trials is an opportunity for patients with cancer to receive not only therapies that are potentially more effective than current standard of care, but also to receive treatment under highly regulated protocols, a practice that likely enhances the quality of care delivered. Working tirelessly to promote the safe and efficient conduct of clinical research, Dr. Bruno is the Medical Director of the William T. Dahms Clinical Research Unit (DCRU) at University Hospitals Cleveland Medical Center. As such, she is responsible for developing and sustaining a productive and effective clinical research unit that supports consortium-wide principal investigators in the process of discovery providing clinical research subjects with novel research studies.
The translational scientific nature of clinical studies goes beyond bridging bench to bedside research, as they may generate practice changing results requiring implementation in the “real world” and often lead to health disparities. Dr. Bruno is particularly interested in studying disparities in lung cancer treatment and developing interventions to overcome them. She has discovered the existence of racial disparities when it comes to comprehensive genomic testing for patients with advanced lung cancer throughout the US and demonstrated that biomarker and NGS testing are independently associated with clinical trial participation. She then proceeded to look at biomarker testing rates in patients with metastatic colorectal cancer throughout the US and found similar racial disparities as well as an independent impact of NGS testing and clinical trial participation. This is a particularly important finding that may explain in part racial inequities when it comes to representation in oncology clinical trials.
At University Hospitals, she has been responsible for developing and implementing a precision medicine service for all patients with advanced/metastatic non-small cell lung cancer. The ultimate goal of this project is to promote ample and equitable biomarker testing, targeted therapy use and clinical trial participation to all patients with advanced non-small cell lung cancer treated at this large hybrid academic-community practice Institution. This quality improvement study/project launched in August 2021, leading to a significant increase not only in biomarker testing rates but also in the detection of genomic alterations that allow for the use of the most efficient targeted therapies. The project ultimately is the result of a close collaboration with University Hospitals Molecular Pathology Lab, diagnostic teams as well as Information Technology services and positively affects at large patients treated by community oncology providers. Since its launch, this service has identified clinical trial eligibility for the majority of the patients tested.
Dr. Bruno is the Co-Chair of the Case CCC Committee on Disparities in Clinical Research. This Committee is invested in assessing and addressing the barriers for achieving equitable representation of minority patients with cancer in all interventional studies at Case CCC.

I am a thoracic medical oncologist at University Hospitals Seidman Cancer Center and an Assistant Professor of Medicine at Case Western Reserve University, specializing in the care of patients with lung cancer, mesothelioma, and thymoma. My primary career objective is to investigate the experiences and optimize the care of long-term survivors of lung cancer patients. This interest has been deeply personal, as both of my parents were diagnosed with non-small cell lung cancer (NSCLC) 6 months apart in 2007. At the time, I was fortuitously working in a lab that was studying EGFR mutations in NSCLC, and I was thus able to influence my father's medical care, helping him to obtain erlotinib off-label for the treatment of his metastatic disease. Although my father unfortunately passed away 16 months after his diagnosis, my mother is a long-term survivor over a decade later. These formative experiences have been the driving force in my pursuit of a career in thoracic oncology.
My research interests in the functional aspects of survivorship such as psychosocial aspects, cognitive dysfunction, and physical function have evolved during my training. During my Internal Medicine residency, I worked with Dr. Lois Travis at Indiana University exploring survivorship in testicular cancer, identifying markers of inflammation which could be tracked longitudinally and inform risk of the development of subsequent cardiovascular disease and metabolic syndrome after platinum chemotherapy. Subsequently, I have found that lung cancer survivors face unique challenges which have changed over the years with the advent of TKI's and immunotherapy. These advances in therapeutic options have resulted in increased survival for many lung cancer patients, and there is now a larger need for lung cancer specific survivorship programming.
My undergraduate psychology experience and my consumer research training at Procter and Gamble have provided me with a background in qualitative research. During my Medical Oncology fellowship, under the mentorship of Dr. Jarushka Naidoo and Dr. Josephine Feliciano, I leveraged my qualitative assessment skills while gaining clinical research experience to identify needs of long-term, advanced stage lung cancer survivors treated with immunotherapy,. Through a qualitative survey of patients, I retrospectively identified that 25% of NSCLC survivors required continued management of long-term toxicities from immunotherapy over one year after the start of their treatment. This was further emphasized in a qualitative interview study done exclusively in survivors with metastatic NSCLC treated with immunotherapy, which identified several themes including long-term psychosocial and physical toxicity, sources of support, financial toxicity, and surveillance. My final fellowship project was a cross-sectional survey exploring physical, social, emotional, financial, and medical needs of patients with all stages of lung cancer which is in the final stages of data analysis. I am expanding this assessment to a more diverse population and will use the preliminary data to inform interventions to address the long-term needs of survivors of lung cancer. I will include patients with small cell lung cancer (SCLC) and emphasize the enrollment of racial and sociodemographical underserved population. My ultimate goal is to study and identify ways to prevent and ameliorate the issues of long-term survivors of lung cancer to provide evidence-based survivorship care.

Dr Vikash was born and brought up in India and belongs to the family of Doctors. His passion and love towards clinical aspects of Medical science push him towards the research field. He is interested in Cardiovascular outcomes research and hospital work includes playing cricket, soccer, volleyball, cooking, and singing.

---

Dr. Rupal Chhabra, DO is an internal medicine specialist in West Harrison, NY and has over 17 years of experience in the medical field. She graduated from New York Institute of Technology College of Osteopathic Medicine in 2006. She is affiliated with medical facilities White Plains Hospital and Phelps Hospital. She is not accepting new patients.

Dr. Rohit Singh, MD is a family medicine specialist in Gurnee, IL and has over 10 years of experience in the medical field. He graduated from Case Western Reserve University in 2013. He is affiliated with Advocate Condell Medical Center. He is not accepting new patients.

Dr. Muhammad Salman Faisal is an internist in Buffalo, New York and is affiliated with . He received his medical degree from King Edward Medical University and has been in practice between 11-20 years.

Dr. Yanjia Zhang, MD works in Boston, MA as a pediatrics specialist.
They are board certified in pediatrics. They are affiliated with Boston Children's Hospital. Their office is not accepting new patients at this time. Dr. Zhang practices at Boston Children's Hospital in Boston, MA.

---

---

I was born and raised in Nawanshahr, Punjab. I did my Medical School training at Government Medical College and Hospital Chandigarh. I took a year hiatus to work in an immunology lab at Weill Cornell Medical College in New York City and then started my residency at Mount Sinai West-Mount Sinai Morningside in New York City. This was followed by a year of training in Palliative Care at Memorial Sloan Kettering Cancer Center. I am currently a first year fellow at Roswell Park Comprehensive Cancer Center.

I am interested in solid tumors (mainly Genitourinary, Gastrointestinal, Thoracic Oncology). I am also interested in advocating for Palliative Care integration in these specialties. I would like to be a physician in an academic setting where I could be involved in designing clinical trials for novel therapies in cancers, also I would like to be involved in medical education involving both oncology and palliative care. I have been on the house staff council and actively involved in the medical education during my residency. I was selected for the Mazumdar/Shaw fellowship at Memorial Sloan Kettering Cancer Center in my Palliative Care Fellowship year for excellence in clinical and research achievements.

I am an avid soccer fan ( you will find me on the weekends watching Arsenal's games, forever gooner), I love to cook (my favorite cuisines are Indian, Italian and French), Fun fact: My alternate career choice would have been a standup comedian.

---

Akshee Batra currently works at the Department of Medicine, Maulana Azad Medical College. Akshee went for 2 months research elective in Sydney Kimmel Cancer Center, Johns Hopkins University and 1 month at NIDDK, NIH. She is interested in dynamic normal functioning of human body and its pathology.

---

---

---

Wafik El-Deiry (born, 1961) is an American physician and cancer researcher who is the Associate Dean for Oncologic Sciences at the , , Director of the Cancer Center at Brown University, and the Director of the Joint Program in Cancer Biology at Brown University and its affiliated hospitals. He was previously deputy director of Translational Research at , where he was also co-Leader of the Molecular Therapeutics Program.